AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.